FREELINE THERAPEUTICS HOLDIN (FRLN) Stock Price, Quote, News and Overview
NASDAQ:FRLN - Nasdaq - US35655L2060 - ADR - Currency: USD
FRLN Quote, Performance and Key Statistics
6.48
0 (0%)
The current stock price of FRLN is 6.48 USD. In the past month the price increased by 1.25%. In the past year, price decreased by -23.58%.
FRLN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About FRLN
Company Profile
Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. The company is headquartered in Stevenage, Hertfordshire and currently employs 152 full-time employees. The company went IPO on 2020-08-07. The firm is developing transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from chronic debilitating diseases. The company uses its rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is advancing FLT201, a differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Therapeutic AAV vectors consist of two main components: the capsid and the expression cassette (that contains the gene and the promoter). The company has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201.
Company Info
FREELINE THERAPEUTICS HOLDIN
Sycamore House, Gunnels Wood Road, Stevenage
Stevenage HERTFORDSHIRE SG1 2FX GB
CEO: Theresa Heggie
Employees: 152
Company Website: https://www.freeline.life/
Phone: 4401438906870
FREELINE THERAPEUTICS HOLDIN / FRLN FAQ
What is the stock price of FREELINE THERAPEUTICS HOLDIN today?
The current stock price of FRLN is 6.48 USD.
What is the ticker symbol for FREELINE THERAPEUTICS HOLDIN stock?
The exchange symbol of FREELINE THERAPEUTICS HOLDIN is FRLN and it is listed on the Nasdaq exchange.
On which exchange is FRLN stock listed?
FRLN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for FREELINE THERAPEUTICS HOLDIN stock?
8 analysts have analysed FRLN and the average price target is 8.41 USD. This implies a price increase of 29.86% is expected in the next year compared to the current price of 6.48. Check the FREELINE THERAPEUTICS HOLDIN stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is FREELINE THERAPEUTICS HOLDIN worth?
FREELINE THERAPEUTICS HOLDIN (FRLN) has a market capitalization of 28.24M USD. This makes FRLN a Nano Cap stock.
How many employees does FREELINE THERAPEUTICS HOLDIN have?
FREELINE THERAPEUTICS HOLDIN (FRLN) currently has 152 employees.
What are the support and resistance levels for FREELINE THERAPEUTICS HOLDIN (FRLN) stock?
FREELINE THERAPEUTICS HOLDIN (FRLN) has a support level at 6.45 and a resistance level at 6.48. Check the full technical report for a detailed analysis of FRLN support and resistance levels.
Should I buy FREELINE THERAPEUTICS HOLDIN (FRLN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of FRLN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of FRLN, evaluating the profitability, health, valuation and growth aspects
- FREELINE THERAPEUTICS HOLDIN (FRLN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- FREELINE THERAPEUTICS HOLDIN (FRLN) Sales and EPS estimates to see what analysts future expectations are.
- FREELINE THERAPEUTICS HOLDIN (FRLN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- FREELINE THERAPEUTICS HOLDIN (FRLN) Insider and Institutional Ownership to learn about the owners and their transactions.
- FREELINE THERAPEUTICS HOLDIN (FRLN) Stock Chart to make your own analysis
- FREELINE THERAPEUTICS HOLDIN (FRLN) Latest news and press-releases to stay up to date.
Does FREELINE THERAPEUTICS HOLDIN (FRLN) stock pay dividends?
FRLN does not pay a dividend.
When does FREELINE THERAPEUTICS HOLDIN (FRLN) report earnings?
FREELINE THERAPEUTICS HOLDIN (FRLN) will report earnings on 2024-02-29, after the market close.
What is the Price/Earnings (PE) ratio of FREELINE THERAPEUTICS HOLDIN (FRLN)?
FREELINE THERAPEUTICS HOLDIN (FRLN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-25.95).
FRLN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to FRLN. When comparing the yearly performance of all stocks, FRLN turns out to be only a medium performer in the overall market: it outperformed 46.8% of all stocks.
FRLN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FRLN. FRLN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
FRLN Financial Highlights
Over the last trailing twelve months FRLN reported a non-GAAP Earnings per Share(EPS) of -25.95. The EPS decreased by -49.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -101.44% | ||
| ROE | -166.21% | ||
| Debt/Equity | 0 |
FRLN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to FRLN. The Buy consensus is the average rating of analysts ratings from 8 analysts.